Effects of SGLT-2 Inhibitors on Cardiac Function, Blood Glucose Levels, and Prognosis in Patients with Type 2 Diabetes Mellitus after Percutaneous Coronary Intervention: A Propensity Score Matching Study

Xiaobing Ni, Long Tang, Chongbing Huang, Quanchao Song, Libo Wang, Sihong Wang
{"title":"Effects of SGLT-2 Inhibitors on Cardiac Function, Blood Glucose Levels, and Prognosis in Patients with Type 2 Diabetes Mellitus after Percutaneous Coronary Intervention: A Propensity Score Matching Study","authors":"Xiaobing Ni, Long Tang, Chongbing Huang, Quanchao Song, Libo Wang, Sihong Wang","doi":"10.59958/hsf.7519","DOIUrl":null,"url":null,"abstract":"Objective: To explore the effect of sodium–glucose cotransporter (SGLT-2) inhibitors on cardiac function, blood glucose level, and prognosis in patients with type 2 diabetes mellitus (T2DM) following percutaneous coronary intervention (PCI). Methods: A retrospective analysis was conducted on the clinical data of 195 patients with T2DM who underwent PCI in our hospital between September 2019 and August 2023. The patients were divided into control and observation groups on the basis of medical records. The general demographic information of all participants was collected. Propensity score matching (PSM) was employed to balance baseline data, allowing for the comparison of good cardiac function rates, cardiac function index levels, blood glucose levels, and adverse reactions after matching. Results: PSM matching was performed in a 1:1 ratio on the 84 patients enrolled in the two groups. The baseline data of the two groups were not statistically significantly different. Compared with those in the control group, the level of left ventricular ejection fraction had significantly increased and levels of left ventricular end-systolic diameter, glycosylated hemoglobin, fasting blood glucose, and 2 h postprandial blood glucose had significantly decreased in the observation group after treatment (p < 0.05). Left ventricular end-diastolic diameter and left ventricular posterior wall thickness (p > 0.05) showed no significant changes. The observation group had a higher rate of good cardiac function (95.24% vs. 80.95%) and lower total incidence of adverse reactions (11.90% vs. 30.95%) than the control group (p < 0.05). Conclusions: SGLT-2 inhibitors can significantly improve cardiac function and blood glucose levels in patients with T2DM after PCI with few adverse reactions and remarkable prognosis recovery effect. Therefore, they can be used in clinical practice.","PeriodicalId":257138,"journal":{"name":"The heart surgery forum","volume":"35 22","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The heart surgery forum","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.59958/hsf.7519","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: To explore the effect of sodium–glucose cotransporter (SGLT-2) inhibitors on cardiac function, blood glucose level, and prognosis in patients with type 2 diabetes mellitus (T2DM) following percutaneous coronary intervention (PCI). Methods: A retrospective analysis was conducted on the clinical data of 195 patients with T2DM who underwent PCI in our hospital between September 2019 and August 2023. The patients were divided into control and observation groups on the basis of medical records. The general demographic information of all participants was collected. Propensity score matching (PSM) was employed to balance baseline data, allowing for the comparison of good cardiac function rates, cardiac function index levels, blood glucose levels, and adverse reactions after matching. Results: PSM matching was performed in a 1:1 ratio on the 84 patients enrolled in the two groups. The baseline data of the two groups were not statistically significantly different. Compared with those in the control group, the level of left ventricular ejection fraction had significantly increased and levels of left ventricular end-systolic diameter, glycosylated hemoglobin, fasting blood glucose, and 2 h postprandial blood glucose had significantly decreased in the observation group after treatment (p < 0.05). Left ventricular end-diastolic diameter and left ventricular posterior wall thickness (p > 0.05) showed no significant changes. The observation group had a higher rate of good cardiac function (95.24% vs. 80.95%) and lower total incidence of adverse reactions (11.90% vs. 30.95%) than the control group (p < 0.05). Conclusions: SGLT-2 inhibitors can significantly improve cardiac function and blood glucose levels in patients with T2DM after PCI with few adverse reactions and remarkable prognosis recovery effect. Therefore, they can be used in clinical practice.
SGLT-2 抑制剂对经皮冠状动脉介入治疗后 2 型糖尿病患者心功能、血糖水平和预后的影响:倾向评分匹配研究
目的探讨钠-葡萄糖共转运体(SGLT-2)抑制剂对经皮冠状动脉介入治疗(PCI)后 2 型糖尿病(T2DM)患者心脏功能、血糖水平和预后的影响。研究方法对2019年9月至2023年8月期间在我院接受PCI治疗的195例T2DM患者的临床资料进行回顾性分析。根据病历将患者分为对照组和观察组。收集了所有参与者的一般人口统计学信息。采用倾向评分匹配法(PSM)平衡基线数据,以便比较匹配后的心功能良好率、心功能指数水平、血糖水平和不良反应。结果:两组的 84 名患者按 1:1 的比例进行了 PSM 匹配。两组的基线数据在统计学上无明显差异。与对照组相比,观察组治疗后左心室射血分数水平明显增加,左心室收缩末期直径、糖化血红蛋白、空腹血糖和餐后 2 小时血糖水平明显下降(P < 0.05)。左心室舒张末期直径和左心室后壁厚度(P > 0.05)无明显变化。与对照组相比,观察组心功能良好率更高(95.24% 对 80.95%),不良反应总发生率更低(11.90% 对 30.95%)(P < 0.05)。结论SGLT-2抑制剂能显著改善PCI术后T2DM患者的心功能和血糖水平,且不良反应少,预后恢复效果显著。因此,SGLT-2 抑制剂可用于临床实践。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信